SEC Tracker
Get the app

Eli Lilly LLY

On November 13, 2025, Eli Lilly CEO David Ricks sold 50,000 shares of LLY stock for a total value of $12.5 million. This significant insider sale signals potential bearish sentiment from company leadership and may raise concerns among investors about the stock's near-term outlook.

Lilly ENDOWMENT INC, insider filing for LLY

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Eli Lilly files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Johnson & Johnson JNJ public float $367.0B, Jun 29, 2025
  2. AbbVie ABBV public float $325.1B, Jun 30, 2025
  3. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  4. Merck MRK public float $198.1B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.